KR101500766B1 - 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법 - Google Patents

치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법 Download PDF

Info

Publication number
KR101500766B1
KR101500766B1 KR1020097011731A KR20097011731A KR101500766B1 KR 101500766 B1 KR101500766 B1 KR 101500766B1 KR 1020097011731 A KR1020097011731 A KR 1020097011731A KR 20097011731 A KR20097011731 A KR 20097011731A KR 101500766 B1 KR101500766 B1 KR 101500766B1
Authority
KR
South Korea
Prior art keywords
dimethoxy
isobutyl
hexahydro
pyrido
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097011731A
Other languages
English (en)
Korean (ko)
Other versions
KR101500766B9 (ko
KR20090079257A (ko
Inventor
카일 더블유. 가노
Original Assignee
뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101500766(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴로크린 바이오사이언시즈 인코퍼레이티드 filed Critical 뉴로크린 바이오사이언시즈 인코퍼레이티드
Publication of KR20090079257A publication Critical patent/KR20090079257A/ko
Application granted granted Critical
Publication of KR101500766B1 publication Critical patent/KR101500766B1/ko
Publication of KR101500766B9 publication Critical patent/KR101500766B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097011731A 2006-11-08 2007-11-08 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법 Active KR101500766B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86494406P 2006-11-08 2006-11-08
US60/864,944 2006-11-08
PCT/US2007/084176 WO2008058261A1 (en) 2006-11-08 2007-11-08 Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Publications (3)

Publication Number Publication Date
KR20090079257A KR20090079257A (ko) 2009-07-21
KR101500766B1 true KR101500766B1 (ko) 2015-03-16
KR101500766B9 KR101500766B9 (ko) 2024-09-25

Family

ID=39110526

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097011731A Active KR101500766B1 (ko) 2006-11-08 2007-11-08 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법

Country Status (16)

Country Link
US (2) US8039627B2 (enExample)
EP (1) EP2081929B1 (enExample)
JP (1) JP5290185B2 (enExample)
KR (1) KR101500766B1 (enExample)
CN (1) CN101553487B (enExample)
AU (1) AU2007317242B2 (enExample)
BR (1) BRPI0718247B1 (enExample)
CA (1) CA2668689C (enExample)
DK (1) DK2081929T3 (enExample)
EA (1) EA018378B1 (enExample)
ES (1) ES2402220T3 (enExample)
IL (1) IL198250A0 (enExample)
MX (1) MX2009004910A (enExample)
PL (1) PL2081929T3 (enExample)
PT (1) PT2081929E (enExample)
WO (1) WO2008058261A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US8524733B2 (en) 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012000308A1 (zh) * 2010-06-29 2012-01-05 中国药科大学 丁苯那嗪的拆分方法
US8351329B2 (en) * 2010-09-14 2013-01-08 Cisco Technology, Inc. Universal load-balancing tunnel encapsulation
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2012081031A1 (en) 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
IN2015DN01662A (enExample) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2899707A1 (en) * 2013-01-31 2014-08-07 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015048370A1 (en) * 2013-09-27 2015-04-02 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
AU2014357518A1 (en) * 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
MX2016009817A (es) 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
CN113368110A (zh) * 2014-02-07 2021-09-10 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
ME03654B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
SI3936130T1 (sl) * 2014-05-06 2024-05-31 Neurocrine Biosciences, Inc., Režim odmerjanja valbenazina za zdravljenje hiperkinetičnih gibalnih motenj
WO2016127133A1 (en) * 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
JP6932641B2 (ja) 2015-03-06 2021-09-08 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
KR20240125709A (ko) * 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
EP3359148A1 (en) 2015-10-09 2018-08-15 Teva Pharmaceuticals International GmbH Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
WO2017182916A1 (en) * 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
ES2811048T3 (es) * 2016-06-29 2021-03-10 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas
EP3523300A1 (en) 2016-10-06 2019-08-14 Assia Chemical Industries Ltd. Solid state forms of valbenazine
TW202515564A (zh) 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
JP7199359B2 (ja) * 2017-01-27 2023-01-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018178243A2 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) * 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
BR112020005373A2 (pt) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
SG11202003194YA (en) * 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3706748A4 (en) * 2017-11-08 2021-08-11 Foresee Pharmaceuticals Co., Ltd. ESTER OF DIHYDROTETRABENAZINE
US11384077B2 (en) 2017-11-22 2022-07-12 Assia Chemical Industries Ltd. Solid state form of Valbenazine
US11339158B2 (en) 2017-12-26 2022-05-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CN110092785A (zh) * 2018-01-31 2019-08-06 广东东阳光药业有限公司 一种丁苯那嗪的动态拆分方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
TW202011963A (zh) * 2018-06-14 2020-04-01 美商紐羅克里生物科學有限公司 Vmat2抑制劑化合物、組合物及其相關方法
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3065236A1 (en) 2018-12-27 2020-06-27 Apotex Inc. Novel crystalline form of valbenazine dibesylate
WO2020213014A1 (en) 2019-04-19 2020-10-22 Mylan Laboratories Limited An improved process for the preparation of valbenazine and its salts
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
CN114302883B (zh) * 2019-08-12 2022-09-06 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4028397A1 (en) 2019-09-13 2022-07-20 Neurocrine Biosciences, Inc. Processes for the synthesis of valbenazine
CN110698397A (zh) * 2019-10-28 2020-01-17 南京红杉生物科技有限公司 丁苯那嗪中间体及其合成方法、应用和合成用中间产物
EP4606429A3 (en) 2021-03-22 2025-12-03 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
JP2024516199A (ja) 2021-04-26 2024-04-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジンの合成方法
WO2023278991A1 (en) 2021-06-30 2023-01-05 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
BR112023026691A2 (pt) 2021-06-30 2024-03-05 Neurocrine Biosciences Inc Valbenazina para uso no tratamento complementar de esquizofrenia
EP4489754A1 (en) 2022-03-07 2025-01-15 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
PE20251750A1 (es) 2022-09-21 2025-07-09 Neurocrine Biosciences Inc Inhibidores de hexahidro-2h-pirido[2,1-a]isoquinolina vmat2 y metodos de uso
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025038938A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of huntington's chorea
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2025199234A1 (en) 2024-03-20 2025-09-25 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2843591A (en) * 1958-07-15 Method for preparing same
US2852518A (en) * 1957-05-23 1958-09-16 Parke Davis & Co Di-substituted quinoline compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
CA2623794A1 (en) 2005-06-29 2007-01-11 The Trustees Of Columbia University In The City Of New York Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
PT1855677E (pt) 2005-08-06 2009-01-13 Cambridge Lab Ireland Ltd 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. J. Med. Chem., 1990, 25, pages 369-374 *

Also Published As

Publication number Publication date
ES2402220T8 (es) 2021-12-23
PT2081929E (pt) 2013-04-15
AU2007317242A1 (en) 2008-05-15
CN101553487B (zh) 2012-06-13
CA2668689A1 (en) 2008-05-15
CA2668689C (en) 2015-12-29
MX2009004910A (es) 2009-07-24
EA200970461A1 (ru) 2009-12-30
JP5290185B2 (ja) 2013-09-18
BRPI0718247A2 (pt) 2014-01-07
KR101500766B9 (ko) 2024-09-25
EP2081929A1 (en) 2009-07-29
ES2402220T3 (es) 2013-04-29
BRPI0718247B1 (pt) 2021-09-21
EA018378B1 (ru) 2013-07-30
US20120077839A1 (en) 2012-03-29
IL198250A0 (en) 2009-12-24
DK2081929T3 (da) 2013-04-15
WO2008058261A1 (en) 2008-05-15
KR20090079257A (ko) 2009-07-21
AU2007317242B2 (en) 2013-08-01
US8039627B2 (en) 2011-10-18
US8357697B2 (en) 2013-01-22
EP2081929B1 (en) 2013-01-09
US20080167337A1 (en) 2008-07-10
JP2010509366A (ja) 2010-03-25
PL2081929T3 (pl) 2013-06-28
CN101553487A (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
KR101500766B1 (ko) 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법
US10399973B2 (en) Compounds I
KR20190032613A (ko) (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
RU2764980C2 (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
EP3822276A1 (en) Heterocyclic compound as trk inhibitor
EP4134366A1 (en) 3-azabicycloalkyl derivative and pharmaceutical composition containing same
EP3988098A1 (en) Heterocyclo alkyl compounds used as ccr2/ccr5 antagonist
WO2017122116A1 (en) 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
EP3592740B1 (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives
KR101950057B1 (ko) 파록세틴 유도체
EP3957638B1 (en) Macrocyclic derivatives acting as xia factor inhibitor
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用
US20230192606A1 (en) Direct thrombin inhibitors and methods of use thereof
WO2023008470A1 (ja) 縮環アミン誘導体
HK40021310A (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives
HK40021310B (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20180226

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190222

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20200225

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 8, Claim Number : 2 9, Period Limitation Text : 457, Comment Text : 16

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 8, Claim Number : 2 9, Period Limitation Text : 457, Comment Text : 16

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-5-5-R10-R15-oth-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-5-5-R10-R16-oth-X000

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20240925

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1015007660000

Gazette reference publication date: 20150316

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301